RE:RE:RE:RE:RE:RE:Pfizer partners with startup Flagship valued at US$7 BillionNoteable wrote: No one said they did. The purpose of this subject was to demonstrate that Big Pharma is prepared to spend Billion$ and is having to reach further upstream in the R&D process in an effort to gain new assets to help stave off the looming patent cliff that they face and replenish their dwindling product portfolios. I can't seek how some on this message board keep missing this overwhelming issue for Big Pharma..
Consequently, Big Pharma will have to increasingly look at negotiating US$ 10 Billion to US$25 Billion M&A valuations to acquire late stage high-vale assets like ONCY's pelareorep, and still avoid FTC scrutiny. A US$10 Billion to US$15 Billion acquistion of ONCY will do both.
would that kind of buyout be worth over $100 per ONC share? :)